Gearoid Faherty, Chief Executive Officer of Eurand N.V. (EURX), presides over the closing bell.

Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Eurand has completed two phase III clinical trials on its lead product candidate, Zentase, for the treatment of exocrine pancreatic insufficiency (EPI) and filed a rolling NDA for this product which the company anticipates to complete by the end of 2007. Eurand's technology platforms include bioavailability enhancement of poorly soluble drugs, customized release, taste-making/fast-dissolving formulations and drug conjugation. Eurand is a global company with facilities in the USA and Europe.

For more information, visit Eurand's website at www.eurand.com.

Organizations interested in obtaining NASDAQ-listed company bell ringing ceremony photographs for press purposes, must first receive approval from the listed company before requesting photographs from NASDAQ. Please provide the company contact information from whom you received approval to Jolene Libretto at jolene.libretto@nasdaq.com. Kindly credit © 2007, The Nasdaq Stock Market, Inc. Reprinted with permission.

For all other photography inquiries, please contact NASDAQ’s photographer, Rob Tannenbaum at rob.tannenbaum@nasdaq.com.

© Copyright 2007, The NASDAQ Stock Market, Inc.
Reprinted with the permission of The Nasdaq Stock Market, Inc.

Copyright | Disclaimer | Trademarks | Privacy Statement | Contact Us | Help | Search